GlobeNewswire·Sep 21, 2026, 7:30 AM ET

Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026

Helus Pharma presented four posters on HLP003 at Psych Congress 2026 in New Orleans from September 15–19, 2026.
The posters evaluated HLP003, an investigational oral deuterated psilocin analog, as a potential adjunctive treatment for major depressive disorder (MDD).
Three presentations detailed 12-month efficacy results & safety data from the completed Phase 1/2a randomized, double-blind study.
The fourth poster provided an overview of the ongoing Phase 3 PARADIGM clinical program evaluating the efficacy & safety of HLP003.
HLP003 has received Breakthrough Therapy Designation from the U.S. FDA for the adjunctive treatment of MDD.
Helus Pharma (trading as Cybin Inc.) is also developing HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder.
The company operates in Canada, the United States, the United Kingdom, & Ireland with a focus on novel serotonergic agonists.
The news release includes standard forward-looking statements & disclaimers regarding the unconfirmed efficacy of the proposed products.